Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Data availability remains a major challenge for radiation therapy dose accumulation for patients' re-treatment and re-irradiation. When a patient moves between radiation therapy providers it is particularly challenging. To address this challenge, a solution was developed for departments in Victoria, Australia, with the ability to request and receive files of any size and type from other providers, supported by a workflow system, an independent security model and a highly secure platform. In the first 5 years there have been 3911 requests for previous treatment details. Of these 2937 (75 %) involved transfer of DICOM data to enable higher quality dose accumulation assessment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12391762 | PMC |
| http://dx.doi.org/10.1016/j.tipsro.2025.100334 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The cachexia index as a prognostic indicator in patients with cervical cancer treated with radiotherapy: A retrospective study.
Nutr Clin Pract
September 2025
Department of Clinical Nutrition, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Objective: The cachexia index (CXI) demonstrates potential as both a diagnostic tool for cachexia and a prognostic tool for survival in cancer. However, CXI's predictive value has not been verified in cervical cancer. The purpose of this study is to investigate the prognostic value of the CXI in patients with cervical cancer treated with radiotherapy.
View Article and Find Full Text PDFA Promising Frontier in Cancer Therapy - Combining Endothelial Colony Forming Cells, Nanotechnology, and Hyperthermia for Precision Oncology.
Stem Cell Rev Rep
September 2025
Paris Cité University, INSERM UMR-S 970, Paris Cardiovascular Research Centre, Paris, France.
Endothelial Colony-Forming Cells (ECFCs) are recognized as key vasculogenic progenitors in humans and serve as valuable liquid biopsies for diagnosing and studying vascular disorders. In a groundbreaking study, Anceschi et al. present a novel, integrative strategy that combines ECFCs loaded with gold nanorods (AuNRs) to enhance tumor radiosensitization through localized hyperthermia.
View Article and Find Full Text PDFASO Practice Guidelines Series: Soft Tissue Sarcoma of the Extremities and Superficial Trunk.
Ann Surg Oncol
September 2025
Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Soft tissue sarcomas (STS) are a heterogeneous group of rare malignant tumors arising from mesenchymal tissues, with extremity and superficial trunk STS (eSTS) comprising the majority of cases. The management of localized eSTS requires a multidisciplinary approach to optimize oncologic and functional outcomes. This review outlines the natural history, diagnostic workup, and treatment principles for localized eSTS, emphasizing the role of histology-specific considerations in guiding management strategies.
View Article and Find Full Text PDFUltrahypofractionated radiotherapy in one or two sessions for localized prostate cancer: a review of the evidence and future perspectives.
Clin Transl Oncol
September 2025
Department of Radiation Oncology, Vithas La Milagrosa University Hospital, Madrid, 28010, Spain.
This narrative review analyzes current evidence comparing single-session and two-session approaches in Stereotactic Body Radiation Therapy (SBRT) and high-dose-rate (HDR) brachytherapy for localized prostate cancer. These ultra-hypofractionated strategies deliver high-precision ablative doses while minimizing exposure to normal tissues. SBRT regimens with fewer than five fractions show tumor control comparable to conventional treatments, offering reduced treatment burden and increased convenience.
View Article and Find Full Text PDFExploring Differentially Expressed Genes and Understanding the Underlying Mechanisms in Glioblastoma.
Biochem Genet
September 2025
Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University Cerrahpasa, Kocamustafapasa, 34098, Istanbul, Turkey.
Glioblastoma is the most aggressive and malignant tumor of the central nervous system. Current treatment options, including surgical excision, radiotherapy, and chemotherapy, have Limited efficacy, with a median survival rate of approximately 15 months. To develop novel therapeutics, it is crucial to understand the underlying molecular mechanisms driving glioblastoma.
View Article and Find Full Text PDF